This study focuses on preventing new-onset diabetes in patients who have received a kidney transplant. After organ transplantation, some patients may develop diabetes as a complication of their treatment. The medication being tested is vildagliptin (also known as LAF237), which is given as tablets in the early period after transplantation.
The purpose of this research is to determine if short-term treatment with vildagliptin can prevent the development of diabetes in the first year after kidney transplantation. The medication is taken by mouth, with patients receiving up to 100 mg daily for a period of 8 weeks. During the study, patients will receive standard medications that help prevent rejection of the transplanted kidney, including tacrolimus, mycophenolic acid, and steroids.
Throughout the study, patients will have their blood sugar levels monitored regularly. Other aspects of health will also be checked, including kidney function, blood composition, and overall well-being. The study will track how many patients develop diabetes within one year after their transplant. Diabetes will be identified through blood sugar measurements or the need for diabetes medication.
France 
